Introduction
In many African settings, women concurrently face substantial risk of human immunodeficiency virus type 1 (
HIV
‐1) infection, sexually transmitted infections (
STI
s) and unintended pregnancies. Few studies have evaluated
STI
risk among users of hormonal implants and copper intrauterine devices (
IUD
s) although these long‐acting reversible contraceptive methods are being promoted widely because of their benefits. Within a prospective study of women at risk for
HIV
‐1, we compared the risk of acquisition of
Chlamydia trachomatis, Neisseria gonorrhoeae
and
Trichomonas vaginalis
among women using different contraceptive methods.
Methods
MTN
‐020/
ASPIRE
was a randomized trial of the dapivirine vaginal ring for
HIV
‐1 prevention among 2629 women aged 18 to 45 years from Malawi, South Africa, Uganda and Zimbabwe, of whom 2264 used copper
IUD
s or progestin‐based injectables or implants during follow‐up. Screening for the above
STI
s occurred semi‐annually.
Results
Over 3440 person‐years of follow‐up, 408 cases of
C. trachomatis
(incidence 11.86/100 person‐years), 196 of
N. gonorrhoeae
(5.70/100 person‐years) and 213 cases of
T. vaginalis
(6.19/100 person‐years) were detected.
C. trachomatis
and
N. gonorrhoeae
incidence were not significantly different across contraceptive methods.
T. vaginalis
incidence was significantly higher for copper
IUD
users compared to depot medroxyprogesterone acetate (
DMPA
), implant and norethisterone enanthate users.
Conclusion
Among African women at high
HIV
‐1 risk,
STI
s were common. Risk of cervical infections did not differ across contraceptive methods. Significantly higher rates of
T. vaginalis
were observed among progestin‐based methods compared to copper
IUD
users. Overall, these findings call for more intensive routine screening for
STI
s, and they support current World Health Organization guidance that women should have a wide range of contraceptive options.